Neo Comprehensive - Solid Tumor

Precision oncology: SIMPLER. BETTER. FASTER.

Neo Comprehensive™ – Solid Tumor provides coverage of cancer-relevant biomarkers across DNA and RNA in a single assay

  • 517 genes by DNA for SNVs and InDels
    • 59 genes by DNA for CNVs
    • 55 genes by RNA for known and novel fusions and splice variants
    • Plus TMB and MSI in a single test
  • PD-L1 IHC option available
    • PD-L1 companion diagnostic matched to tumor type
  • New, SIMPLER and BETTER report
  • Reduced FFPE tissue requirements – only 10 slides
    • Lower occurrences of QNS/TNP leads to more prompt delivery of results for a higher number of patients

ORDER NEO COMPREHENSIVE - SOLID TUMOR NOW

Brought to you by the market leader in Oncology Diagnostics for over 20 years. With over 1.7 million cancer-related tests per year, and an extensive range of over 500 clinical cancer tests available, we are your trusted laboratory for all of your cancer-testing needs.

Why CGP?

Simultaneous assessment of multiple biomarkers in a single assay has numerous benefits over single-gene assays:

Optimizes your testing strategy by comprehensively covering all clinically relevant genes, including both diagnostic and prognostic markers and markers that will influence participation in clinical trials

  • Provides information on both common and rare oncogenic drivers in a single test
  • Increases actionable data output versus single-gene testing
  • Saves time, costs less, and conserves tissue specimens
    • With so many drug targets for certain cancers, it would require less tissue specimen to do CGP testing
  • Recommended by national guidelines

 

Why Neo Comprehensive - Solid Tumor?

  • Assess patient’s diagnosis and prognosis
  • Develop therapeutic strategies quickly with only 10-day turnaround time when sent directly to San Diego laboratory!
  • Wide-spectrum screening of genetic markers beyond those found in cancer-specific profiles, in order to identify less frequent markers that cancer-specific profiles could miss
  • Identify relevant clinical trials for patients

COMING SOON

 

Easy order through NeoAccess - Streamlined, online ordering platform with built-in advanced clinical decision support to simplify biomarker testing

COMING SOON

 

Includes NeoSeek - A platform that enables you to visualize all of your previous patient's NeoGenomics data and export them into a report

Gene fusions involving common actionable genes are highly prevalent in the clinical setting

An analysis of 6,009 tumors across 14 cancer types found that 7.2% of tumors expressed a gene fusion involving one of 19 actionable gene families/pathways targeted by an approved therapy1

RNA-based NGS for more accurate detection of fusion

DNA sequencing may be used to detect fusions, but RNA sequencing has been shown to have higher sensitivity.2  In an analysis of 254 lung adenocarcinomas found to be negative for gene fusions and METex14 alterations by a DNA-based assay, previously undetected alterations were identified by RNA sequencing in 14% of patients.2


“Targeted RNAseq assays should be used in all cases that appear driver-negative by DNAseq assays to ensure comprehensive detection of actionable gene rearrangements.”2

One-stop solution for accurate, comprehensive genomic profiling.

The test profile includes 517 genes by DNA for SNVs and InDels, 59 genes by DNA for CNVs, and 55 genes by RNA for known and novel fusions and splice variants.

In addition, Neo Comprehensive assesses:

  • TMB from over 1.94 megabases (Mb) of DNA sequences.
  • MSI status from 130 known homopolymer regions.
DNA content in Neo Comprehensive – Solid Tumor
ABL1 BCR CHEK1 EPHA7 FGF8 GSK38 IDH2 MAP3K1 NF2 PIK3CA RAD51D SMAD4 TGFBR2
ABL2 BIRC3 CHEK2 EPHB1 FGF9 H3F3A IFNGR1 MAP3K13 NFE2L2 PIK3CB RAD52 SMARCA4 TMEM127
ACVR1 BLM CIC; ERBB2 FGF10 H3F3B INHBA MAP3K14 NFKBIA PIK3CD RAD54L SMARCB1 TMPRSS2
ACVR1B BMPR1A CREBBP ERBB3 FGF14 H3F3C INPP4A MAP3K4 NKX2-1 PIK3CG RAF1 SMARCD1 TNFIP3
AKT1 BRAF CRKL ERBB4 FGF19 HGF INPP4B MAPK1 NKX3-1 PIK3R1 RANBP2 SMC1A TNFRSF14
ATK2 BRCA1 CRLF2 ERCC1 FGF23 HIST1H1C INSR MAPK3 NOTCH1 PIK3R2 RARA SMC3 TOP1
AKT3 BRCA2 CSF1R ERCC2 FGFR1 HIST1H2B IRF2 MAX NOTCH2 PIK3R3 RASA1 SMO TOP2A
ALK BRD4 CSF3R ERCC3 FGFR2 HIST1H3A IRF4 MCL1 NOTCH3 PIM1 RB1 SNCAIP TP53
ALOX12B BRIP1 CSNK1A1 ERCC4 FGFR3 HIST1H3B IRS1 MDC1 NOTCH4 PLCG2 RBM10 SOCS1 TP63
ANKRD11 BTG1 CTCF ERCC5 FGFR4 HIST1H3C IRS2 MDM2 NPM1 PLK2 RECQL4 SOX10 TRAF2
ANKRD26 BTK CTLA4 ERG FH HIST1H3D &JAK1 MDM4 NRAS MPAIP1 REL SOX17 TRAF7
APC C11orf30 CTNNA1 ERRFl1 FLCN HIST1H3E JAK2 MED12 NRG1 PMS1 RET SOX2 TSC1
AR CALR CTNNB1 ESR1 FLl1 HIST1H3F JAK3 MEF2B NSD1 PMS2 RFWD2 SOX9 TSC2
ARAF CARD11 CUL3 ETS1 FLT1 HIST1H3G JUN MEN1 NTRK1 PNRC1 RHEB SPEN TSHR
ARFRP1 CASP8 CUX1 ETV1 FLT3 HIST1H3H KAT6A MET NTRK2 POLD1 RHOA SPOP U2AF1
ARID1A CBFB CXCR4 ETV4 FLT4 HIST1H3l KDM5A MGA NTRK3 POLE RICTOR SPTA1 VEGFA
ARID1B CBL CYLD ETV5 FOXA1 HIST1H3J KDM5C MITF NUP93 PPARG RIT1 SRC VHL
ARID2 CCND1 DAXX ETV6 FOXL2 HIST2H3A KDM6A MLH1 NUTM1 PPM1D RNF43 SRSF2 VTCN1
ARID5B CCND2 DCUN1D1 EWSR1 FOXO1 HIST2H3C KDR MLL PAK1 PPPR1A ROS1 STAG1 WISP3
ASXL1 CCND3 DDR2 EXH2 FOXP1 HIST2H3D KEAP1 MLLT3 PAK3 PPP2R2A RPS6K2A STAG2 WT1
ASXL2 CCNE1 DDX41 FAM123B FRS2 HIST3H3 KEL MPL PAK7 PPP6C RPS6KB1 STAT3 XIAP
ATM CD274 DHX15 FAM175A FUBP1 HLA-A KIF5B MRE11A PALB2 PRDM1 RPS6KB2 STAT4 XPO1
ATR CD276 DICER1 FAM46C FYN HLA-B KIT MSH2 PARK2 PREX2 RPTOR STAT5A XRCC2
ATRX CD74 DIS3 FANCA GABRA6 HLA-C KLF4 MSH3 PARP1 PRKAR1A RUNX1 STAT5B YAP1
AURKA CD79A DNAJB1 FANCC GATA1 HNF1A KLHL6 MSH6 PAX3 PRKCl RUNX1T1 STK11 YES1
AURKB CD79B DNMT1 FANCD2 GATA2 HNRNPK KMT2B MST1 PAX5 PRKDC RYBP STK40 ZBTB2
AXIN1 CDC73 DNMT3A FANCE GATA3 HOXB13 KMT2C MST1R PAX7 PRSS8 SDHA SUFU XBTB7A
AXIN2 CDH1 DNMT3B FANCF GATA4 IGF1 KMT2D MTOR PAX8 PTCH1 SDHAF2 SUZ12 ZFHX3
AXL CDK12 DOT1L FANCG GATA6 IGF1R KRAS MUTYH PNRM1 PTEN SDHB SYK ZNF217
B2M CDK4 E2F3 FANCl GEN1 IGF2 LAMP1 MYB PDCD1 PTPN11 SDHC TAF1 ZNF703
BAP1 CDK6 EED FANCL GID4 IKBKE LATS1 MYC PDCD1LG2 PTPRD SDHD TBX3 ZRSR2
BARD1 CDK8 EGFL7 FAS GLl1 lKZF1 LATS2 MYCL1 PDGFRA PTPRS SETBP1 TCEB1  
BBC3 CDKN1B EGFR FAT1 GNA11 lL10 LM01 MYCN PDGFRB PTPRT SETD2 TCF3  
BCL10 CDKN1B ElF1AX FBXW7 GNA13 lL7R LRP1B MYD88 PDK1 QKl SF3B1 TCF7L2  
BCL2 CDKNA2 ElF4A2 FGF1 GNAQ INHA LYN MYOD1 PDPK1 RAB35 SH2B3 TERC  
BCL2L1 CDKN2B ElF4E FGF2 GNAS HRAS LZTR1 NAB2 PGR RAC1 SH2D1A TERT  
BCL2L11 CDKN2C EML4 FGF3 GPR124 HSD3B1 MAGl2 NBN PHF6 RAD21 SHQ1 TET1  
BCL2L2 CEBPA EP300 FGF4 GPS2 HSP90AA1 MALT1 NCOA3 PHOX2B RAD50 SLIT2 TET2  
BCL6 CENPA EPCAM FGF5 GREM1 ICOSLG MAP2K1 NCOR1 PIK3C2B RAD51 SLX4 TFE3  
BCOR CHD2 EPHA3 FGF6 GRIN2A ID3 MAP2K2 NEGR1 PIK3C2G RAD51B SMAD2 TFRC  
BCORL1 CHD4 EPHA5 FGF7 GRM3 IDH1 MAP2K4 NF1 PIK3C3 RAD51C SMAD3 TGFBR1  

Shaded content is analyzed for CNVs detection in addition to SNVs and InDels

 

RNA content in Neo Comprehensive – Solid Tumor

All genes listed are assessed for known and novel fusions; shaded content is analyzed for splice variants.

ABL1 EGFR FGFR2 MLL PAX3
AKT3 EML4 FGFR3 MLLT3 PAX7
ALK ERBB2 FGFR4 MSH2 PDGFRA
AR ERG FLl1 MYC PDGFRB
AXL ESR1 FLT1 NOTCH1 PIK3CA
BCL2 ETS1 FLT3 NOTCH2 PPARG
BRAF ETV1 JAK2 NOTCH3 RAF1
BRCA1 ETV4 KDR NRG1 RET
BRCA2 ETV5 KIF5B NTRK1 ROS1
CDK4 EWSR1 KIT NTRK2 RPS6KB1
CSF1R FGFR1 MET NTRK3 TMPRSS2

 

All genes listed are assessed for known and novel fusions; shaded content is analyzed for splice variants.

Immunotherapy Markers included in Neo Comprehensive – Solid Tumor

Microsatellite Instability (MSI):

  • MSI-high is defined as ≥20% of loci showing instability
  • Microsatellite-stable (MSS) is defined as <20% of loci showing instability

Tumor Mutational Burden (TMB):

  • TMB-high is defined as ≥10.0 mut/Mb (mutations per megabase)
  • TMB-low is defined as <10.0 mut/Mb

Resources

Test Requisition Form
Order Neo Comprehensive for Your Patients
NEOACCESS - SIMPLE, ONLINE ORDERING PLATFORM FOR ONCOLOGISTS

NeoAccess is a powerful online tool with built-in Advanced Decision Support to place testing orders, simplify and streamline biomarker testing and viewing patient reports for oncologists.

COMING SOON
Client Services

NeoGenomics prides itself on our unparalleled customer support team. If you have questions regarding test information, specimen requirements, turnaround times, test add-on, and patient results, please feel free to reach out to a Client Services Advocate at client.services@neogenomics.com or call 866.776.5907, option 3.

VIEW OUR COMPREHENSIVE TESTING MENU
REQUISITION FORMS

Call the NeoGenomics Client Services team at 866.776.5907 and press 3 to order test requisitions and kits, or to inquire about setting up online ordering through NeoLINK®.

ACCESS FORMS
ONLINE ORDERS

Online Orders streamlines and simplifies your test ordering process into a single, time-saving, easy-to-use experience.

LOG IN TO NEOLINK

Best-in-class support, getting you and your patients to the answers you need quickly and efficiently.

At NeoGenomics, we take great pride in our unparalleled customer support team. Every one of our clients is assigned to their own Client Services Advocate to make sure we deliver the service that you deserve. Each Client Services Advocate has been trained to handle any of your questions and is knowledgeable in the services we provide, such as our testing menu, typical turnaround times, and add-ons. They are your first point of contact with us and will immediately direct your call to speak with our medical experts if required.

* 10-day turnaround time is dependent upon the sample being shipped to the San Diego laboratory.

CGP = comprehensive genomic profiling; CNVs = copy number variants; FFPE = formalin-fixed paraffin-embedded; IHC = immunohistochemistry; InDels = insertions and deletions; MSI = microsatellite instability; NGS = next-generation sequencing; PD-L1 = programmed cell death ligand 1; QNS = quantity not sufficient; SNVs = single nucleotide variants; TMB = tumor mutation burden; TNP = test not performed.

References: 1. Lopez-Diaz FJ, et al. ASCO Annual Meeting, June 3-7, 2022. Abstract e18804. 2. Benayed R, et al. Clin Cancer Res. 2019;25(15):4712-4722.